EU Filing Expected by Year-end '04 Using Previously Completed Phase III Clinical Results; Agreement Signed with New Contract Manufacturer for Europe and U.S.

10-10-2003

Nabi Biopharmaceuticals announced it is significantly accelerating its timeline for licensing and commercializing its lead development product, StaphVAX (S. aureus polysaccharide conjugate vaccine). StaphVAX is an investigational vaccine being developed to prevent S. aureus blood stream ...

more

Advancement Toward Potential Treatment and Prevention of SARS to be Presented at Scientific Conference

10-10-2003

Presenting on October 11, 2003 at the annual meeting of the Infectious Disease Society of America, a team of scientists from the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) in Jamaica Plain and at the Medical School's Worcester campus, in ...

more

License agreements with the University of Chicago guarantee exclusive worldwide rights to the most important groups of patents in the field of oncolytic Herpes Simplex Viruses (HSV)

09-10-2003

The German-American biotechnology company MediGene (Frankfurt, Prime Standard: MDG) has acquired additional patents and patent applications for the anti-cancer drug candidates NV1020 and G207 as well as for the underlying HSV technology. License agreements concluded with the University of ...

more

09-10-2003

MorphoSys AG announced today that the first promising animal data from preclinical studies for its anti-inflammatory antibody programs MOR101 and MOR102 have been presented at the Human Antibodies & Hybridomas Conference in Osaka, Japan. The antibody programs MOR101 and MOR102 target ICAM-1, ...

more

08-10-2003

The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry for 2003 "for discoveries concerning channels in cell membranes", with one half of the prize to Peter Agre, Johns Hopkins University School of Medicine, Baltimore, USA "for the discovery of water ...

more

08-10-2003

This was the first year that this annual award competition, which is organized by Deutsche Messe AG, was held. The award was presented on October 6 at the opening ceremony of BioTechnica 2003 in Hannover, Germany. The award is devoted to small and medium-sized European enterprises in the ...

more

CDL to Provide Diverse Compound Collection and Chemistry Services to Support the Discovery of New Antibacterial Agents

02-10-2003

Mpex Pharmaceuticals, Inc. ("Mpex") and Chemical Diversity Labs, Inc. ("CDL") announced that they have entered into an agreement where CDL will provide Mpex with a diverse library of 100,000 small molecule compounds to support the discovery of new antibacterial agents. In addition to compound ...

more

Pharmaceutical giant refreshes IT infrastructure to speed drug development cycle and enhance operational efficiency

02-10-2003

Intel and Novartis, a world leader in pharmaceuticals, today announced Novartis has adopted an Intel(R) Pentium(R) 4 processor powered PC grid platform as a strategic part of its 5-year plan for extending R&D capabilities. The PC refresh programme forms part of enhancements to the ...

more

01-10-2003

Cambridge, UK - Astex Technology, the fragment-based drug discovery company, is ranked 12th in the Sunday Times ARM Tech Track 100 league of Britain's fastest growing technology companies, published Sunday 28th September. Astex is one of only a small group of biotechnology companies to have ...

more

01-10-2003

Baxter Healthcare Corporation and Miltenyi Biotec GmbH announced today that they have signed an agreement whereby Miltenyi Biotec will have exclusive rights for five years to distribute, market and sell Baxter's cellular therapy products worldwide, with the exception of China, Japan, Korea ...

more